• Subjects aged ≥ 18 years.

• Histologically confirmed relapsed or refractory CD-19+ malignancy, including: non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), Chronic Lymphocytic Leukemia (CLL)/Richter's syndrome. CD-19+ must be confirmed by immunohistochemistry or flow cytometry analysis.

• Subjects who have relapsed or refractory disease after failing at least 2 or more prior lines of therapy.

• ECOG Performance Status ≤ 2.

• Life expectancy \> 12 weeks.

• Willing to consent to 15 years of follow-up as part of IRB 110692: Long-Term Evaluation of the Biology and Outcomes of Hematopoietic Stem Cell Transplantation

• Adequate organ function as defined as:

‣ Hematologic:

• Absolute neutrophil count (ANC) ≥ 500/mm3

∙ Platelet count ≥ 10,000/mm3

∙ Hemoglobin ≥ 8 g/dL

⁃ Hepatic:

• Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN).

∙ AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN

⁃ Renal:

• Serum Creatinine ≤ 2 x institutional upper limit of normal (ULN) or eGFR \>30 ml/min/1.73m2

• For subjects of childbearing potential: Negative pregnancy test or evidence of post-menopausal status or evidence of permanent surgical sterilization. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

‣ Subjects \< 50 years of age:

• Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and

∙ Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution

⁃ Subjects ≥ 50 years of age:

• Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or

∙ Had radiation-induced menopause with last menses \>1 year ago; or

∙ Had chemotherapy-induced menopause with last menses \>1 year ago

• Subjects of childbearing potential and subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1.

• Recovery to baseline or ≤ Grade 2 CTCAE v5.0 from toxicities related to any prior cancer therapy, unless considered stable by the treating investigator.

• Adequate venous access.

• Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

• Step 2 Eligibility Confirmation

‣ The following criteria must be confirmed within 7 days prior to lymphodepletion. If all criteria are not met, lymphodepletion should be delayed.

• Confirmation of successful CAR-T manufacturing.

∙ No evidence or suspicion of an infection.

∙ Serum Creatinine ≤ 2 x institutional upper limit of normal (ULN) or eGFR \>30 ml/min/1.73m2

∙ No worsening of clinical status compared to either the initial eligibility criteria that would, in the opinion of the treating physician, significantly increase the risk from lymphodepleting chemotherapy or exclude them from treatment with study CAR-T therapy.

• Step 3 Eligibility Confirmation

‣ The following criteria must be confirmed prior to CAR-T therapy. If all criteria are not met, CAR-T therapy should be delayed.

• No worsening of clinical status compared to either the initial eligibility criteria that would, in the opinion of the treating physician, significantly increase the risks from treatment with CAR-T therapy.

∙ Confirmation that washout periods outlined in section 6.6 and Appendix 10 have been followed.